Encompass Health
EHC
$106.46
+5.00%
Encompass Health Corporation is a leading provider of post-acute healthcare services in the United States, operating a national network of inpatient rehabilitation hospitals. The company is a pure-play, market-leading operator in the inpatient rehabilitation facility (IRF) segment, specializing in rehabilitative care for patients recovering from complex medical conditions. The current investor narrative centers on the company's ability to deliver steady organic growth within a stable, reimbursement-driven industry, with recent attention on its consistent capital return policy, as evidenced by its regular dividend declarations, and its performance amidst broader healthcare labor and cost pressures.…
EHC
Encompass Health
$106.46
Related headlines
Investment Opinion: Should I buy EHC Today?
Rating & Thesis: Hold. EHC is a fundamentally sound company trapped in a bearish trend, making it a 'Show Me' story where investors should wait for evidence of a technical reversal or catalyst before committing new capital. The limited analyst coverage prevents a strong consensus anchor, placing greater weight on the stock's own price action.
Supporting Evidence: The hold rating is supported by four key data points. First, valuation is reasonable at a forward P/E of 15.50x, below its historical average. Second, revenue growth remains healthy at ~10% YoY. Third, profitability is robust with a net margin of 9.46% and strong TTM FCF of $439.2M. Fourth, the stock offers a modest dividend yield of 0.67%. However, these positives are counterbalanced by the stock's 1-year decline of 16.63% and severe underperformance versus the market.
Risks & Conditions: The two biggest risks are the continuation of the technical downtrend and a deterioration in quarterly margins. This Hold rating would upgrade to a Buy if the stock sustains a break above key resistance near $110, signaling a trend reversal, or if the forward P/E compresses further toward 14x while growth remains intact. It would downgrade to a Sell if the stock breaks decisively below its 52-week low of $92.77 or if quarterly revenue growth decelerates below 5%. Relative to its history, the stock appears fairly valued to slightly undervalued, but relative to current market momentum, it remains out of favor.
Sign up to view all
EHC 12-Month Price Forecast
EHC presents a classic value vs. momentum conflict. The fundamentals—steady growth, profitability, and cash flow—support a higher valuation, but the price action tells a story of persistent distribution and investor apathy. The neutral stance reflects this stalemate. Confidence is medium because while the numbers are clear, the catalyst for a sentiment shift is not. The stance would upgrade to bullish on a confirmed technical reversal above $110 coupled with stable margins. It would turn bearish on a breakdown below $92.77, which would validate the downtrend and likely lead to further multiple compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Encompass Health's 12-month outlook, with a consensus price target around $138.40 and implied upside of +30.0% versus the current price.
Average Target
$138.40
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$85 - $138
Analyst target range
Analyst coverage for EHC appears limited, with the provided data indicating only 2 analysts providing estimates for revenue and EPS. This suggests the stock is not widely covered by major sell-side institutions, which is common for mid-cap healthcare services companies and can lead to higher volatility and less efficient price discovery. The average revenue estimate for the period is $8.935 billion, with a narrow range between $8.904 billion and $8.968 billion, indicating strong consensus on the top-line outlook. The lack of explicit price targets and buy/hold/sell ratings in the provided dataset further underscores the limited analyst coverage, placing greater emphasis on fundamental and technical analysis for investment decisions.
Bulls vs Bears: EHC Investment Factors
The evidence presents a clear tension between solid, defensive fundamentals and persistent negative price action. The bull case is anchored in EHC's stable revenue growth (9.94% YoY), strong cash flow ($439M TTM FCF), and valuation discount (P/E of 18.89x vs. historical >20x). The bear case is driven by the stock's severe technical downtrend (-16.63% YoY), significant market underperformance (-35.77% relative strength), and high short interest (ratio 4.08). Currently, the bearish technical and sentiment factors hold stronger evidence, as they reflect the market's current voting mechanism. The single most important tension is whether the market will begin to reward EHC's stable fundamentals and valuation discount, or if the negative momentum and sector headwinds will continue to compress its multiples further.
Bullish
- Robust Revenue Growth & Stability: Q4 2025 revenue grew 9.94% YoY to $1.544B, demonstrating consistent mid-to-high single-digit growth in a stable, reimbursement-driven industry. This organic growth is driven by the company's core inpatient rehabilitation segment, providing a predictable revenue stream.
- Strong Profitability & Cash Generation: The company maintains solid profitability with a Q4 net margin of 9.46% and generates substantial free cash flow, with TTM FCF of $439.2M. This strong cash generation supports a consistent dividend policy and provides capacity for shareholder returns and reinvestment.
- Attractive Valuation vs. History: The trailing P/E of 18.89x is below its 2-year historical average, which has frequently been above 20x, suggesting a discount to its own valuation range. The forward P/E of 15.50x implies the market expects earnings growth and further multiple compression.
- Defensive Low-Beta Profile: With a beta of 0.595, EHC is approximately 40% less volatile than the broader market. This defensive characteristic is attractive for risk-averse investors, especially during market downturns, as evidenced by its smaller 1-month decline (-2.84%) compared to SPY's -2.86%.
Bearish
- Sustained Technical Downtrend: The stock is down 16.63% over the past year, significantly underperforming the SPY's 19.14% gain, and is trading 21% below its 52-week high of $127.99. This persistent downtrend indicates strong selling pressure and a lack of positive momentum.
- Limited Analyst Coverage & Visibility: Only 2 analysts provide estimates for EHC, indicating limited institutional coverage which can lead to higher volatility and less efficient price discovery. The absence of explicit price targets in the data makes it harder to gauge consensus expectations.
- Margin Pressure & Earnings Volatility: While revenue is growing, quarterly net income has shown fluctuations (e.g., $146.1M in Q4 2025 vs. $151.5M in Q1 2025). The gross margin of 22.78% in the latest quarter, though specific to its reporting, suggests potential sensitivity to healthcare labor and cost pressures.
- High Short Interest: A short ratio of 4.08 indicates significant bearish sentiment from short sellers. This elevated short interest can act as a headwind for the stock price and reflects market skepticism about near-term prospects.
EHC Technical Analysis
The stock is in a sustained downtrend, having declined 16.63% over the past year, significantly underperforming the broader market which is up 19.14%. As of the latest close at $101.33, the price is trading approximately 21% above its 52-week low of $92.77 but nearly 21% below its 52-week high of $127.99, positioning it in the lower-middle portion of its annual range, which suggests the stock is not at a clear oversold extreme but is facing significant resistance. Recent short-term momentum shows mixed signals, with a 3-month gain of 3.85% but a 1-month decline of 2.84%, indicating recent weakness within a tentative recovery attempt from the lows seen in late March. The stock's beta of 0.595 indicates it is approximately 40% less volatile than the broader market (SPY), which is typical for a defensive healthcare services company and suggests it should exhibit less downside risk in turbulent markets. Key technical levels are clearly defined, with the 52-week high of $127.99 representing major overhead resistance and the 52-week low of $92.77 acting as critical support; a decisive break below this support would signal a continuation of the primary downtrend, while a sustained move above the descending trendline near $110 would be needed to suggest a meaningful reversal.
Beta
0.60
0.60x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$93-$128
Price range past year
Annual Return
-10.4%
Cumulative gain past year
| Period | EHC Return | S&P 500 |
|---|---|---|
| 1m | +4.8% | -1.9% |
| 3m | +9.3% | +13.6% |
| 6m | +0.1% | +9.0% |
| 1y | -10.4% | +20.0% |
| ytd | +0.1% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EHC Fundamental Analysis
Revenue growth remains healthy and consistent, with the most recent Q4 2025 revenue of $1.544 billion representing a 9.94% year-over-year increase, continuing a multi-quarter trend of mid-to-high single-digit growth driven by its core inpatient rehabilitation segment. Profitability is robust, with the company generating a net income of $146.1 million in Q4 2025, translating to a net margin of 9.46%, and a gross margin of 22.78%; while quarterly net income has fluctuated, the trailing twelve-month free cash flow of $439.2 million demonstrates strong cash generation. The balance sheet and cash flow profile are solid, with a debt-to-equity ratio of 1.11 indicating moderate leverage, a current ratio of 1.08 showing adequate short-term liquidity, and a trailing twelve-month free cash flow of $439.2 million providing ample capacity for dividends, share repurchases, and capital expenditures to support hospital expansions.
Quarterly Revenue
$1.5B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.22%
Latest Quarter
Free Cash Flow
$439199999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EHC Overvalued?
Given the company's consistent profitability (Net Income > 0), the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio stands at 18.89x, while the forward P/E is lower at 15.50x, indicating the market anticipates earnings growth and a modest multiple compression. Compared to the provided historical data, the current trailing P/E of 18.89x is below the 2-year historical average observed in the quarterly data, which has frequently been above 20x, suggesting the stock is trading at a discount to its own historical valuation range. This historical discount, combined with the forward P/E of 15.50x, implies the market may be pricing in concerns about future growth deceleration or margin pressure, despite the company's stable fundamentals.
PE
18.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 14x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: EHC faces moderate financial risk from its debt-to-equity ratio of 1.11, though this is manageable. A more pressing operational risk is margin pressure, as evidenced by the fluctuating quarterly net income (from $151.5M in Q1 2025 to $146.1M in Q4 2025) and a gross margin of 22.78% in its latest quarter, which could be squeezed by persistent healthcare labor cost inflation. Furthermore, the company's revenue is concentrated in its sole inpatient rehabilitation segment, making it vulnerable to changes in Medicare/Medicaid reimbursement rates, which are a primary driver of its top-line growth.
Market & Competitive Risks: The primary market risk is valuation compression. Despite trading at a discount to its own history (P/E 18.89x), the stock's sustained downtrend suggests the market is applying a de-rating, possibly due to concerns over growth deceleration in a mature industry. Its low beta of 0.595 offers some defensive protection but does not shield it from sector-specific rotations out of healthcare services stocks. Competitive risks include pressure from alternative post-acute care settings and potential regulatory changes that could impact patient volumes or pricing power.
Worst-Case Scenario: The worst-case scenario involves a combination of a significant Medicare reimbursement cut, a severe escalation in wage inflation that crushes margins, and a broader market sell-off that hits defensive stocks. This could trigger a break below the critical 52-week low support of $92.77, confirming the primary downtrend. Given the stock's 52-week high of $127.99 and a historical max drawdown of -26.22%, a realistic adverse scenario could see the stock re-testing its lows, implying a potential downside of approximately -8.5% from the current price of $101.33 to the 52-week low of $92.77. A breach of that level could lead to further declines towards the $85-$90 range.
FAQ
The key risks are, in order of severity: 1) Technical & Sentiment Risk: The sustained downtrend (-16.63% YoY) and high short interest (ratio 4.08) could persist, leading to further capital erosion regardless of fundamentals. 2) Operational Risk: Fluctuating quarterly earnings and potential margin pressure from healthcare labor costs, as seen in variable net income figures. 3) Regulatory Risk: Dependence on stable Medicare/Medicaid reimbursement rates for its sole inpatient rehab segment. 4) Market Risk: Continued underperformance relative to the market (1-year relative strength -35.77%) if the sector remains out of favor.
The 12-month forecast presents three scenarios. The Bull Case (25% probability) targets $118-$128, driven by a valuation re-rating and positive catalysts. The Base Case (60% probability) targets $100-$115, expecting the stock to remain range-bound as steady execution battles negative momentum. The Bear Case (15% probability) targets $85-$95, triggered by an earnings miss and a break below key support. The Base Case is most likely, predicated on the assumption that EHC's stable fundamentals prevent a collapse but lack a spark to ignite a major rally in the near term.
EHC appears fairly valued to slightly undervalued based on its own history. Its trailing P/E of 18.89x is below its 2-year historical average, which has frequently been above 20x. The forward P/E of 15.50x suggests the market expects modest earnings growth. Compared to the broader market's growth, the multiple seems reasonable for a company with ~10% revenue growth and a 9.46% net margin. The valuation implies the market is paying a fair price for steady, defensive growth but is not assigning any premium for market leadership or acceleration.
EHC is a conditional buy for value-oriented, patient investors. At a forward P/E of 15.50x, it trades at a discount to its own history, and its 9.94% revenue growth and strong free cash flow ($439M TTM) are attractive. However, its 1-year decline of 16.63% and high short interest (ratio 4.08) signal significant bearish sentiment. It is a good buy for those who believe the fundamentals will eventually be rewarded and are willing to wait for a technical catalyst, such as a break above $110. For traders or those seeking momentum, it is not a good buy currently.
EHC is more suitable for a long-term investment horizon of 2-3 years minimum. Its low beta (0.595) and defensive business model align with a buy-and-hold strategy where investors can collect the dividend and wait for valuation normalization. The stock's lack of positive momentum and high short interest make it a poor candidate for short-term trading. The long-term thesis relies on the company's ability to compound earnings and cash flow steadily, which requires time for the market to recognize. A minimum holding period of 18-24 months is suggested to weather near-term volatility and allow the fundamental story to play out.